- Home
- VIGL vs CUE Comparison
VIGL vs CUE Comparison
Compare VIGL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- CUE
- Stock Information
- Founded
- VIGL 2020
- CUE 2014
- Country
- VIGL United States
- CUE United States
- Employees
- VIGL N/A
- CUE N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- CUE Health Care
- Exchange
- VIGL Nasdaq
- CUE Nasdaq
- Market Cap
- VIGL 74.7M
- CUE 60.6M
- IPO Year
- VIGL 2022
- CUE 2018
- Fundamental
- Price
- VIGL $1.81
- CUE $0.79
- Analyst Decision
- VIGL Strong Buy
- CUE Strong Buy
- Analyst Count
- VIGL 5
- CUE 3
- Target Price
- VIGL $16.33
- CUE $3.00
- AVG Volume (30 Days)
- VIGL 141.7K
- CUE 211.2K
- Earning Date
- VIGL 05-06-2025
- CUE 05-08-2025
- Dividend Yield
- VIGL N/A
- CUE N/A
- EPS Growth
- VIGL N/A
- CUE N/A
- EPS
- VIGL N/A
- CUE N/A
- Revenue
- VIGL N/A
- CUE $9,287,000.00
- Revenue This Year
- VIGL N/A
- CUE N/A
- Revenue Next Year
- VIGL N/A
- CUE $4.77
- P/E Ratio
- VIGL N/A
- CUE N/A
- Revenue Growth
- VIGL N/A
- CUE 69.16
- 52 Week Low
- VIGL $1.31
- CUE $0.45
- 52 Week High
- VIGL $6.06
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- VIGL 53.10
- CUE 41.54
- Support Level
- VIGL $1.31
- CUE $0.74
- Resistance Level
- VIGL $1.66
- CUE $0.83
- Average True Range (ATR)
- VIGL 0.16
- CUE 0.09
- MACD
- VIGL 0.06
- CUE 0.02
- Stochastic Oscillator
- VIGL 97.24
- CUE 63.66
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.